Company*
(Country; Symbol)

University/
Non-Profit

Type Of Agreement

Product Area

Details (Date)


Advancis Pharmaceu-
tical
Corp.*

The Institute for Genomic Research

Research and license agreement

Comparison of Advancis' Pulsys-delivered antibiotics on microbial expression profiles with those of microbes exposed to traditional dosing schemes

The goal is to evaluate the effect of amoxicillin on Streptococcus pneumoniae expression profiles (9/25)

Agilent Technol-
ogies
Inc.
(NYSE:A)

Royal Netherlands Academy of Science institutes

Technology access agreement

DNA microarrays and a microarray scanner

The technology will be used by the Netherlands Brain Research Institute for the study of neurological diseases and peripheral and central nervous system regeneration, and the Netherlands Ophthalmic Research Institute, which will research age-related macular degeneration, glaucoma and retinitis pigmentosa (10/1)

Antisoma plc
(UK; ASOM;
LSE:ASM)

National Institutes
of Health

Licensing agreement

Enzyme, recombinant cytotoxic RNase

Antisoma acquired exclusive worldwide rights to RNase, in combination with monoclonal antibodies that target PEM and CEA - protein targets found on certain cancer cells (9/10)

Atrix Lab-
oratories
Inc.
(ATRX)

Tulane University Health Sciences Center

Exercised option licensing agreement

Human growth hormone releasing peptide-1

Atrix will develop the compound using its sustained-release Atrigel delivery technology (9/10)

Avigen
(AVGN)

Lawrence Berkeley Laboratory

Exclusive worldwide license

Interest in a patent covering a potential Parkinson's disease therapy

Avigen has exclusive rights to a family of U.S. and European patent applications; Avigen also has the right to sublicense any eventual patents to third parties (8/27)

Biophage
Inc.*

Public Works and Government Services Canada

Contracts

Immune defense mechanisms to fight anthrax and plague infections

The contracts are worth C$0.58M (US$0.37M) and are part of a bigger agreement the company has with the Department of National Defense and the Defense Research Establishment Suffield (10/16)

BresaGen
Inc.
(Australia;
BSGNY;
ASX:BGN)

Monash University
in Melbourne

Collaboration

New stem cell research facility

BresaGen will team up with the university's research groups to exploit applications of human embryonic stem cell technology; the new facility is being funded by the Australian government (8/24)

Celera
Genomics
Group
(NYSE:
CRA) and
Applied
Bio-
systems Group
(NYSE:ABI)

The SNP
Consortium

Contract agreement

Data for a genome-wide SNP-based linkage map for genetic analysis

The map will consist of 2,000 SNPs selected from the consortium's database that will be validated by Celera using Applied Biosystems' TaqMan reagent system (8/28)

Charles
River Lab-
oratories Inc.
(NYSE:CRL)

Medical College of Wisconsin in Milwaukee

Distribution agreement

Consomic rat models

The models are designed to allow researchers to study the specific function of particular genes that contribute to common multigenic human diseases of the heart, lung and blood (9/27)

Common-
wealth
Bio-
technologies
Inc.
(CBTE)

Unnamed
government sponsor

Contract

To perform detailed DNA sequence analyses of particular organisms for strain differentiation

The contract is expected to generate nearly $800,000 over the next five years, with $200,000 anticipated in the first year of the contract (9/26)

Entomed SA
(France)*

Shanghai Institute
of Entomology

Collaboration

Insect extracts

Entomed intends to develop new drugs using the extracts for a range of therapeutic areas (10/15)

Esperion
Therapeutics
Inc.
(ESPR)

University of Michigan

License agreement

Paraoxonase technology

Exclusive rights agreement for Esperion to develop the technology; Esperion will pay the university license fees, maintenance fees, milestone payments and royalties (10/1)

Galapagos
Genomics
NV
(the
Netherlands)*

Flanders Interuniversity Institute of Biotechnology (VIB)

Collaboration

Drug targets against Alzheimer's disease

Collaboration is to identify and validate the drug targets; genes identified that modulate gamma-secretase activity will be further validated as potential drugs or targets by Galapagos and a group from VIB (8/30)

Genetastix
Corp.*

Development Center for Biotechnology (Taiwan)

Access agreement

Genetastix's HuMyTech platform

DCB will use the platform to generate fully human monoclonal antibodies against entrovirus type 71; Genetastix will receive research and development payments, milestone payments and royalties (10/10)

Hybrigenics
SA
(France)*

Institut
Pasteur

Exclusive collaboration

Functional proteomics

Agreement is for infectious diseases and is an extension to a 1998 agreement (10/15)

Integrative
Proteomics
Inc.

(Canada)*

University
of Toronto

Joint research and licensing agreement

To functionally map certain pathogenic bacterial proteomes

The effort will receive more than $9M in funding from the Ontario Research and Development Challenge Fund (10/1)

InterCell
Biomedical
Research
and Develop-
ment AG
(Austria)*

Centre for Applied Microbiology and Research

Licensing agreement

Antigen discovery technology

The technology will help develop vaccines against a range of infectious diseases; hepatitis C will be the first target (9/26**)

Introgen
Therapeutics
Inc.
(INGN)

M.D. Anderson Cancer Center

Licensing agreement

Sequenced genes that play roles in suppressing and preventing development of lung and other cancers

The technologies have been added to Introgen's broad exclusive license agreement with M.D. Anderson (10/11)

LigoCyte
Pharmaceu-
ticals
Inc.*

National Institute
of Allergy and
Infectious Diseases

Cooperative research and development agreement

Rabies DNA vaccine

The vaccine is targeted to mucosal tissues in the nose and mouth; LigoCyte will provide its M-cell targeting technology (9/18)

MediGene
AG
(Germany;
Neuer Markt:
MDG)

Children's Hospital
in Boston

Expanded licensing agreement

Herpes simplex virus-based amplicon technology

The exclusive worldwide license entitles MediGene to use the HSV amplicon technology for all prophylactic and therapeutic applications in humans as well as for commercial research purposes (9/6)

MediGene
AG
(Germany;
Neuer Markt:
MDG)

Memorial Sloan-Kettering Cancer Center

Exclusive option agreement

Intellectual property for cancer treatment

The agreement is for property regarding the use of chemotherapy in combination with MediGene's proprietary oncolytic herpes simplex viruses to treat cancer (8/22**)

Medivir AB
(Sweden)*

Michael Curtis at Barts, the London School of Medicine and Dentistry, Queen Mary and the University of London

Collaboration

Antibiotics

The project aims to use a novel and highly focused applied genomics approach to develop protease inhibitors as specific antimicrobials against M. tuberculosis, H. pylori, P. aeruginosa and S. aureus (8/27)

Modex
Therapeu-
tics
Inc.
(Switzerland;
SWX:MDXN)

University
of Geneva

Exclusive license agreement

Technology covering a family of small-peptide molecules

The molecules can be used to modulate the location and number of melanocytes in the epidermis (10/1)

NaPro
BioThera-
peutics Inc.
(NPRO)

University of Alabama at Birmingham

Exclusive worldwide licensing agreement

A broad technology relating to any receptor ligand peptides conjugated to any taxane

The technology includes paclitaxel (9/11)

Ocean
Pharmaceu-
ticals
Inc.*

University of Linkoping
(Sweden)

In-licensing agreement

Three compounds in the anti-inflammatory field

The agreement is with a scientist at the university for the compounds with new mechanisms of action in the anti-inflammatory field; the first focus will be in asthma (9/10)

Orchid
BioSciences
Inc.
(ORCH)

Oklahoma Medical Research Foundation

Genotyping service agreement

SNP scoring on samples provided by OMRF

The collaboration is focused on the analysis of SNPs related to autoimmune diseases (9/25)

Oxigene Inc.
(OXGN)

National Eye Institute

Materials- cooperative research and development agreement

To study the effects of Combretastin on an animal model of proliferative diabetic retinopathy

Oxigene retains all rights for non-systemic uses of CA4P (9/26)

Peregrine
Pharmaceu-
ticals
Inc.
(PPHM)

University of Texas

Exclusive worldwide licenses

Cancer compounds

Peregrine licensed technology that uses antibodies that target phosphatidylserine on the surface of tumor endothelial cells, and an antibody, 2C3, that neutralizes vascular endothelial growth factor (8/29)

Phylos
Inc.*

Lawrence Livermore National Laboratory

Development partnership

High-throughput methods for protein production to create research reagents and microarrays

The reagents and microarrays may be used to design new drugs or diagnostic tools (10/11)

Prana
Biotech-
nology Ltd.
(Australia;
PRNAF;
ASX:PBT)

Massachusetts General Hospital

Cross- relationship agreement

Pramipexole

Prana will pay for a portion of Alzheimer's disease research; Prana receives an exclusive license to the patent application for use of pramipexole, which is being tested in patients with Parkinson's disease (8/31)

Pyro-
sequencing
AB
(Sweden;
SSE:PYRO)

University of Geneva

Sponsored research agreement

Analyze genes and develop diagnostic tests for Down's syndrome

The parties will do the work using Pyrosequencing technology (8/29)

Pyro-
sequencing
AB
(Sweden;
SSE:PYRO)

Stuart C. Clarke
of the Scottish Meningococcus
and Pneumococcus Reference Labor-
atory, Stobhill
Hospital

Research collaboration

To investigate applications for Pyrosequencing in infectious bacterium Neisseria meningitidis

The bacterium is the leading cause of meningococcus worldwide (9/26)

RegeneRx
Biopharma-
ceuticals
Inc.
(OTC
BB:RGRX)

University of Texas SouthWestern Medical Center

Materials transfer agreement

Thymosin beta 4 in the cardiac field

The company will provide quantities of T_4, as well as expertise and data, to the university; the company may use any invention or discovery for internal research purposes and retains an option to negotiate an exclusive, worldwide, royalty-bearing license for commercialization (8/30)

Revotar
Biopharma-
ceuticals
AG
(Germany;
subsidiary
of Texas Bio-
technology
Corp.; TXBI)

Fraunhofer
Institute

Licensing agreement

Macrophage migration inhibitory factor

Revotar expects the collaboration to lead to the identification of a lead clinical candidate next year (10/8)

SafeScience
Inc.
(SAFS)

Massachusetts Institute of Technology

Sponsored research program

GBC-590

The program will focus on GBC-590 and identification of other compounds with promising biochemical and pharmaceutical activity (9/19)

Samaritan
Pharmaceu-
ticals
Inc.
(OTC BB:
SPHC)

Georgetown University

Exclusive worldwide license

Cholesterol-recognition amino-acid sequence

Georgetown granted Samaritan an exclusive worldwide license to commercialize the sequence (9/11)

Synthon
Chiragenics
Corp.*

Michigan State University

Collaboration

Biochemistry technology

Under the new, four-year expanded partnership deal, Synthon will receive exclusive worldwide rights to the technology; Synthon will provide $1.1M to support research efforts, plus royalties (9/6)

Tranzyme
Inc.*

Cystic Fibrosis Foundation Therapeutics Inc. (a non-profit affiliate of the Cystic Fibrosis Foundation)

Partnership

Novel cell lines to be used for cystic fibrosis drug discovery

Resulting cell lines will be available to the cystic fibrosis research community; Tranzyme will receive research and development support; they will share future revenue from these cell lines (10/9)

Tranzyme
Inc.*

University of Utah

Collaboration

Bioinformatics and applied genomics

The parties will jointly develop gene libraries using the university's sequence database (10/17)

Virax
Holdings
Ltd.
(Australia;
ASX:VHL)

Michael Brown of Royal Adelaide Hospital's Cancer Center

Collaboration

Immune-based therapy to treat prostate cancer

The vaccine to be developed will use Virax's platform technology, Co-X-Gene, in fowlpox virus vector (8/21)


Notes:

This chart does not include grant agreements (unless they are also part of a larger collaboration) or agreements between biotech companies and clinical trial centers.

* Denotes privately held company.

** Denotes the date the item ran in BioWorld International.

Unless otherwise noted, shares are traded on the Nasdaq exchange.

AMEX = American Stock Exchange; ASX = Australia Stock Exchange; CDNX = Canadian Venture Exchange; LSE = London Stock Exchange; OTC BB = Over the Counter Bulletin Board; NYSE = New York Stock Exchange; SSE = Stockholm Stock Exchange; SWX = Swiss Stock Exchange; TSE = Toronto Stock Exchange

No Comments